Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Glycoprotein / GP (virus)

Glycoprotein / GP (virus)

Brief Information

Name:Envelope glycoprotein
Target Synonym:GP1,2,GP,Envelope glycoprotein
Number of Launched Drugs:2
Number of Drugs in Clinical Trials:2
Lastest Research Phase:Approved

Product ListCompare or Buy

ACRO Quality

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Atoltivimab/Maftivimab/Odesivimab REGN3470-3471-3479; REGN-EB3 Approved Regeneron Pharmaceuticals Inc Inmazeb United States Hemorrhagic Fever, Ebola Regeneron Pharmaceuticals Inc 2020-10-14 Hemorrhagic Fever, Ebola Details
Ansuvimab VRC-EBOMAB092-00-AB; MAb114; MAb-114 Approved National Institute Of Allergy And Infectious Diseases (Niaid), National Institute of Health, Islamabad Ebanga United States Hemorrhagic Fever, Ebola Ridgeback Biotherapeutics Lp 2020-12-21 Hemorrhagic Fever, Ebola Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Porgaviximab/Larcaviximab/Cosfroviximab c2G4-N; c4G7; c13C6 Phase 3 Clinical Mapp Biopharmaceutical, Public Health Agency Of Canada'S National Microbiology Laboratory Hemorrhagic Fever, Ebola Details
MIL-77 MIL-77 Phase 1 Clinical Beijing Mabworks Biotech Co Ltd, Zhejiang Hisun Pharmaceutical Co Ltd, Institute Of Basic Medicine Academy Of Military Medical Sciences Hemorrhagic Fever, Ebola Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message